Form 8-K AN2 Therapeutics, Inc. For: Apr 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq set to open higher as CPI, bank earnings take focus; IBM tumbles
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
AN2 Therapeutics enters $80 million share sale agreement with Jefferies
April 9, 2026 5:07 PM EDTAN2 Therapeutics Inc. (NASDAQ: ANTX) entered into an agreement with Jefferies LLC on April 9, 2026, to potentially sell up to $80 million of common stock through at-the-market offerings.
Under the sales agreement, AN2 may issue and sell shares at its discretion through... More
